Literature DB >> 6087890

Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents.

Y Pommier, R E Schwartz, K W Kohn, L A Zwelling.   

Abstract

The biochemical characteristics of the formation and disappearance of intercalator-induced DNA double-strand breaks (DSB) were studied in nuclei from mouse leukemia L1210 cells by using filter elution methodology [Bradley, M. O., & Kohn, K.W. (1979) Nucleic Acids Res. 7, 793-804]. The three intercalators used were 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA), 5-iminodaunorubicin (5-ID), and ellipticine. These compounds differ in that they produced predominantly DNA single-strand breaks (SSB) (m-AMSA) or predominantly DNA double-strand breaks (ellipticine) or a mixture of both SSB and DSB (5-ID) in whole cells. In isolated nuclei, each intercalator produced DSB at a frequency comparable to that which is produced in whole cells. Moreover, these DNA breaks reversed within 30 min after drug removal. It thus appeared that neither ATP nor other nucleotides were necessary for intercalator-dependent DNA nicking-closing reactions. The formation of the intercalator-induced DSB was reduced at ice temperature. Break formation was also reduced in the absence of magnesium, at a pH above 6.4 and at NaCl concentrations above 200 mM. In the presence of ATP and ATP analogues, the intercalator-induced cleavage was enhanced. These results suggest that the intercalator-induced DSB are enzymatically mediated and that the enzymes involved in these reactions can catalyze DNA double-strand cleavage and rejoining in the absence of ATP, although the occupancy of an ATP binding site might convert the enzyme to a form more reactive to intercalators. Three inhibitors of DNA topoisomerase II--novobiocin, nalidixic acid, and norfloxacin--reduced the formation of DNA strand breaks.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6087890     DOI: 10.1021/bi00309a013

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  19 in total

1.  Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.

Authors:  Dhriti Sooryakumar; Thomas S Dexheimer; Beverly A Teicher; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2011-06-02       Impact factor: 6.261

Review 2.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

3.  Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

Authors:  William Guerrant; Vishal Patil; Joshua C Canzoneri; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

4.  Comparative effects of doxorubicin and 4'-epi-doxorubicin on nucleic acid metabolism and cytotoxicity in a human tumor cell line.

Authors:  O Cantoni; P Sestili; F Cattabeni; C Geroni; F Giuliani
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Poly(ADP-ribose) polymerases PARP1 and PARP2 modulate topoisomerase II beta (TOP2B) function during chromatin condensation in mouse spermiogenesis.

Authors:  Mirella L Meyer-Ficca; Julia D Lonchar; Motomasa Ihara; Marvin L Meistrich; Caroline A Austin; Ralph G Meyer
Journal:  Biol Reprod       Date:  2011-01-12       Impact factor: 4.285

6.  Cellular and molecular pharmacology of 4'-epidoxorubicin in HeLa cells. Comparison with its parent drug, doxorubicin.

Authors:  O Cantoni; P Sestili; F Cattabeni; C Geroni; M Grandi; F C Giuliani
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

Review 7.  Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.

Authors:  N Osheroff; A H Corbett; S H Elsea; M Westergaard
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.

Authors:  Yu-Lun Chen; Tsung-Ying Yang; Kun-Chieh Chen; Chieh-Liang Wu; Shih-Lan Hsu; Chi-Mei Hsueh
Journal:  Cell Oncol (Dordr)       Date:  2016-06-15       Impact factor: 6.730

Review 9.  DNA topoisomerase II as a target of antineoplastic drug therapy.

Authors:  L A Zwelling
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

Review 10.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.